All In Biotech

Drug Trial Radar · NCT01414855

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

A Phase II, Open-Label, Multicenter Study of Efficacy, Safety, and Biomarkers in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma Treated With GA101 (RO5072759) in Combination With CHOP Chemotherapy

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

100

Actual

Start

Aug 31, 2011

Primary completion

Dec 31, 2013

Study completion Dec 23, 2016

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, multicenter study will evaluate the efficacy and safety of obinutuzumab \[RO5072759 (GA101)\] in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemotherapy in patients with advanced diffuse large B-cell lymphoma. Patients will receive 8 cycles of obinutuzumab (1000 mg intravenously on Day 1 of each 21-day cycle, during Cycle 1 obinutuzumab will also be infused on Days 8 and 15) in combination with CHOP chemotherapy on Day 1 of cycles 1 to 6. A substudy will investigate the drug-drug interaction of obinutuzumab with CHOP chemotherapy agents. For the substudy, an additional cohort of approximately 15 patients are planned to be enrolled at a subset of investigational sites.

Conditions

  • Lymphoma, B-Cell

Interventions

  • obinutuzumabDrug

    1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.

  • cyclophosphamideDrug

    750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.

  • doxorubicinDrug

    50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.

  • prednisoneDrug

    100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.

  • vincristineDrug

    1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response (CR) Rate as Assessed by the Investigator at the End of TreatmentTime frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)
  2. Overall Response Rate (ORR) as Assessed by the Investigator at the End of TreatmentTime frame: From the first dose of study treatment to end of treatment response assessment (approximately 228 to 258 days)

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • cCare

    Encinitas, California

  • University of Colorado Cancer Center Department of Hematology

    Aurora, Colorado

  • Rocky Mountain Cancer Ctr - Denver (Williams)

    Denver, Colorado

  • Norwalk Hospital

    Norwalk, Connecticut

  • Florida Cancer Specialists; Department of Oncology

    Fort Myers, Florida

  • Florida Cancer Specialists; Saint Petersburg

    St. Petersburg, Florida

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia

  • Kootenai Medical Center

    Coeur d'Alene, Idaho

  • Northwestern University; Robert H. Lurie Comp Can Ctr

    Chicago, Illinois

  • Onc Hem Assoc of Central IL

    Peoria, Illinois

  • McFarland Clinic

    Ames, Iowa

  • Jewish Cancer Care

    Louisville, Kentucky

  • University of Massachusetts Medical School

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • MT Cancer Inst Fndtn; MT Can Spec

    Missoula, Montana

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • MSKCC at Basking Ridge

    Basking Ridge, New Jersey

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • San Juan Oncology Associates

    Farmington, New Mexico

  • Memorial Sloan-Kettering; Cancer Center

    Commack, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • MSKCC at Mercy Med Ctr

    Rockville Centre, New York

  • MSKCC at Sleepy Hollow

    Sleepy Hollow, New York

  • Emerywood Hematology and Onc

    High Point, North Carolina

  • Willamette Valley Cancer Insitute and Research Center

    Springfield, Oregon

  • Medical University of SC (MUSC)

    Charleston, South Carolina

  • SCRI-Tennessee Oncology

    Nashville, Tennessee

  • Onc & Hem Assoc; USO Cent Pharm

    Fort Worth, Texas

  • MD Anderson Cancer Center Department of Lymphoma & Myeloma

    Houston, Texas

  • Methodist Hospital Research Institute

    Houston, Texas

  • Cancer Therapy & Research Center

    San Antonio, Texas

  • USO - Tyler Cancer Ctr

    Tyler, Texas

  • Blue Ridge Cancer Care - Roanoke

    Roanoke, Virginia

  • Medical Oncology Associates

    Spokane, Washington

  • Northwest Cancer Specialists - Vancouver

    Vancouver, Washington

  • Yakima Valley Memorial Hospital/North Star Lodge

    Yakima, Washington

  • Aurora Bay Care Medical Center

    Green Bay, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.